vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and UNIVERSAL TECHNICAL INSTITUTE INC (UTI). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $220.8M, roughly 1.3× UNIVERSAL TECHNICAL INSTITUTE INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 5.8%, a 90.5% gap on every dollar of revenue. On growth, UNIVERSAL TECHNICAL INSTITUTE INC posted the faster year-over-year revenue change (9.6% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 9.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.
ACAD vs UTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $220.8M |
| Net Profit | $273.6M | $12.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 7.1% |
| Net Margin | 96.3% | 5.8% |
| Revenue YoY | 9.4% | 9.6% |
| Net Profit YoY | 90.3% | -42.1% |
| EPS (diluted) | $1.61 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $220.8M | ||
| Q3 25 | $278.6M | $222.4M | ||
| Q2 25 | $264.6M | $204.3M | ||
| Q1 25 | $244.3M | $207.4M | ||
| Q4 24 | $259.6M | $201.4M | ||
| Q3 24 | $250.4M | $196.4M | ||
| Q2 24 | $242.0M | $177.5M | ||
| Q1 24 | $205.8M | $184.2M |
| Q4 25 | $273.6M | $12.8M | ||
| Q3 25 | $71.8M | $18.8M | ||
| Q2 25 | $26.7M | $10.7M | ||
| Q1 25 | $19.0M | $11.4M | ||
| Q4 24 | $143.7M | $22.2M | ||
| Q3 24 | $32.8M | $18.8M | ||
| Q2 24 | $33.4M | $5.0M | ||
| Q1 24 | $16.6M | $7.8M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 7.1% | ||
| Q3 25 | 12.8% | 11.2% | ||
| Q2 25 | 12.2% | 6.9% | ||
| Q1 25 | 7.9% | 8.1% | ||
| Q4 24 | 59.1% | 13.6% | ||
| Q3 24 | 12.6% | 13.3% | ||
| Q2 24 | 12.6% | 4.2% | ||
| Q1 24 | 7.4% | 6.1% |
| Q4 25 | 96.3% | 5.8% | ||
| Q3 25 | 25.8% | 8.4% | ||
| Q2 25 | 10.1% | 5.2% | ||
| Q1 25 | 7.8% | 5.5% | ||
| Q4 24 | 55.4% | 11.0% | ||
| Q3 24 | 13.1% | 9.6% | ||
| Q2 24 | 13.8% | 2.8% | ||
| Q1 24 | 8.0% | 4.2% |
| Q4 25 | $1.61 | $0.23 | ||
| Q3 25 | $0.42 | $0.33 | ||
| Q2 25 | $0.16 | $0.19 | ||
| Q1 25 | $0.11 | $0.21 | ||
| Q4 24 | $0.86 | $0.40 | ||
| Q3 24 | $0.20 | $0.35 | ||
| Q2 24 | $0.20 | $0.09 | ||
| Q1 24 | $0.10 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $162.8M |
| Total DebtLower is stronger | — | $101.4M |
| Stockholders' EquityBook value | $1.2B | $335.9M |
| Total Assets | $1.6B | $834.0M |
| Debt / EquityLower = less leverage | — | 0.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $162.8M | ||
| Q3 25 | $258.0M | $169.1M | ||
| Q2 25 | $253.6M | $70.7M | ||
| Q1 25 | $217.7M | $96.0M | ||
| Q4 24 | $319.6M | $172.0M | ||
| Q3 24 | $155.1M | $161.9M | ||
| Q2 24 | $177.1M | $115.5M | ||
| Q1 24 | $204.7M | $116.1M |
| Q4 25 | — | $101.4M | ||
| Q3 25 | — | $87.1M | ||
| Q2 25 | — | $73.8M | ||
| Q1 25 | — | $94.4M | ||
| Q4 24 | — | $120.1M | ||
| Q3 24 | — | $125.7M | ||
| Q2 24 | — | $137.3M | ||
| Q1 24 | — | $141.9M |
| Q4 25 | $1.2B | $335.9M | ||
| Q3 25 | $917.3M | $328.1M | ||
| Q2 25 | $822.4M | $306.8M | ||
| Q1 25 | $765.2M | $293.9M | ||
| Q4 24 | $732.8M | $280.0M | ||
| Q3 24 | $577.2M | $260.2M | ||
| Q2 24 | $516.7M | $239.4M | ||
| Q1 24 | $464.0M | $232.6M |
| Q4 25 | $1.6B | $834.0M | ||
| Q3 25 | $1.3B | $826.1M | ||
| Q2 25 | $1.2B | $740.8M | ||
| Q1 25 | $1.1B | $720.4M | ||
| Q4 24 | $1.2B | $753.8M | ||
| Q3 24 | $976.9M | $744.6M | ||
| Q2 24 | $914.1M | $706.0M | ||
| Q1 24 | $855.1M | $702.1M |
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.57× | ||
| Q1 24 | — | 0.61× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $3.1M |
| Free Cash FlowOCF − Capex | — | $-19.2M |
| FCF MarginFCF / Revenue | — | -8.7% |
| Capex IntensityCapex / Revenue | — | 10.1% |
| Cash ConversionOCF / Net Profit | -0.18× | 0.24× |
| TTM Free Cash FlowTrailing 4 quarters | — | $16.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $3.1M | ||
| Q3 25 | $74.3M | $57.1M | ||
| Q2 25 | $64.0M | $18.1M | ||
| Q1 25 | $20.3M | $-789.0K | ||
| Q4 24 | $40.4M | $23.0M | ||
| Q3 24 | $63.2M | $67.5M | ||
| Q2 24 | $25.0M | $10.0M | ||
| Q1 24 | $29.1M | $-2.5M |
| Q4 25 | — | $-19.2M | ||
| Q3 25 | $73.9M | $40.6M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $-11.7M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | $63.2M | $60.0M | ||
| Q2 24 | — | $3.0M | ||
| Q1 24 | — | $-8.4M |
| Q4 25 | — | -8.7% | ||
| Q3 25 | 26.5% | 18.3% | ||
| Q2 25 | — | 3.4% | ||
| Q1 25 | — | -5.7% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | 25.2% | 30.6% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | -4.6% |
| Q4 25 | — | 10.1% | ||
| Q3 25 | 0.1% | 7.4% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | 0.0% | 3.8% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | -0.18× | 0.24× | ||
| Q3 25 | 1.03× | 3.04× | ||
| Q2 25 | 2.40× | 1.69× | ||
| Q1 25 | 1.07× | -0.07× | ||
| Q4 24 | 0.28× | 1.04× | ||
| Q3 24 | 1.93× | 3.58× | ||
| Q2 24 | 0.75× | 2.01× | ||
| Q1 24 | 1.76× | -0.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
UTI
| UTI | $142.8M | 65% |
| Concorde | $78.0M | 35% |
